All News

Take a look back at our most popular news from December 2022.

Take a look back at the top 15 articles that we published in 2022.

Take a look back at our most popular dermatology coverage for 2022.

Take a look back at our most popular Total Pharmacy coverage for 2022.

Take a look back at our most popular pain management coverage for 2022.

Take a look back at our most popular podcast episodes and videos for 2022.

Take a look back at our most popular conference coverage for 2022.

Your weekly roundup of the latest news from Drug Topics®.

Take a look back at our most popular biosimilars coverage for 2022.

Take a look back at our most popular pediatric coverage for 2022.

Take a look back at our most popular respiratory coverage for 2022.

Winner of SingleCare's Best of the Best: Best Pharmacist, Nguyen joined Drug Topics® to discuss how he's helped patients during adverse conditions and what makes for a successful patient encounter.

Your weekly roundup of the latest news from Drug Topics®.

With supply chain issues impacting many industries, drug shortages have occurred. How does the FDA address them?

Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.

Winner of SingleCare's Best of the Best: Best Pharmacy Technician, Santon joined Drug Topics® to discuss what pharmacy technicians can do for patients and why it's so important to her for every patient to afford their medication.

A group of pharmacists rose to the occasion to help a man having a medical emergency aboard a recent United flight bound for Newark, New Jersey.

Your weekly roundup of the latest news from Drug Topics®.

Mark Cuban’s Cost Plus Drugs business has entered into agreements with Capital Blue Cross and Rightway.

Seven of the 10 top selling drugs with high price increases lack the clinical evidence to justify those increases.

Pharmacists can optimize medication adherence and serve as an additional touchpoint for patients during treatment.

Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.

Your weekly roundup of the latest news from Drug Topics®.

Lecanemab is an investigational anti-amyloid beta antibody to treat mild cognitive impairment due to Alzheimer’s disease. It is currently under review by the FDA and a decision is expected by January 6, 2023.

The treatment is approved for preventing recurrent Clostridioides difficile infections.

A look at what’s to come in the December issue of Drug Topics®

Privacy rules to improve coordination of care, avoid discrimination in treatment.

Take a look back at our most popular news from November 2022.